Theravance Biopharma, Inc.
TBPH
Theravance Biopharma, Inc., a biopharmaceutical company, discovers, develops, and commercializes respiratory medicines in the United States, Europe, and Asia. The company offers YUPELRI, a once-daily, nebulized long-acting muscarinic antagonist used for the treatment of chronic obstructive pulmonary disease (COPD). Its product portfolio also include Izencitinib, a gut-selective pan-janus kinase (Jā¦ read more
Healthcare
Biotechnology
11 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$14.75
Price-0.81%
-$0.12
1Y
Price
Market Cap
$742.829m
Small
Price/Earnings 3y Avg5y Avg
61.5x
Premium
Premium
Financials Overview
Key metrics over the past few years+285.5%
EBITDA Margin+209.3%
Net Profit Margin+794.2%
Free Cash Flow MarginRevenue
$77.205m
+19.9%
1y CAGR+14.6%
3y CAGR+9.2%
5y CAGREarnings
$13.031m
+123.1%
1y CAGR+53.8%
3y CAGR+53.7%
5y CAGREPS
$0.24
+120.9%
1y CAGR+42.2%
3y CAGR+45.7%
5y CAGRBook Value
$224.848m
$426.035m
Assets$201.187m
Liabilities$46.457m
DebtDebt to Assets
10.9%
1x
Debt to EBITDAFree Cash Flow
$244.776m
+2162.7%
1y CAGR+768.9%
3y CAGR+579.5%
5y CAGRFinancial Reports
Earnings and other important metrics. Amounts in USD.No items found.
Press Releases
Statements and updates from the company